我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

瑞舒伐他汀联合贝那普利对阵发性心房颤动患者的治疗效果及其作用机制

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第3期
页码:
296-298
栏目:
临床研究
出版日期:
2014-03-20

文章信息/Info

Title:
Therapeutic efficacy and mechanism of rosuvastatin combined with benazepril in patients with paroxysmal atrial fibrillation
作者:
田飞飞; 魏子秀; 徐勤成; 孙晓斐
(济宁市第一人民医院心内科，山东 济宁 272013)
Author(s):
TIAN Fei fei;  WEI Zi xiu;  XU Qin cheng;  SUN Xiao fei
(Department of Cardiology, Jining First People’s Hospital, Jining 272013, Shandong, China)
关键词:
瑞舒伐他汀; 贝那普利; 心房颤动; 阵发性
Keywords:
rosuvastatin;  benazepril;  atrial fibrillation;  paroxysmal
分类号:
R541.71
DOI:
-
文献标识码:
A
摘要:
目的:观察瑞舒伐他汀与贝那普利联合应用对阵发性房颤的治疗效果及其作用机制。方法:入选70例阵发性房颤患者，随机分为试药组（口服胺碘酮+瑞舒伐他汀+贝那普利）及对照组（口服胺碘酮），比较两组患者房颤治疗效果、C反应蛋白（CRP）水平及左房内径（LAD）。结果:经过6个月的随访，与对照组比较，试药组房颤发作次数、房颤持续时间显著下降，总有效率提高，差异均具有显著性(P<005)。且CPR水平、LAD显著低于对照组(均P<0.05)。结论:瑞舒伐他汀联合贝那普利可以减少房颤发生，其机制可能与减少炎症反应，抑制心肌重构有关。
Abstract:
AIM:To observe the therapeutic efficacy and mechanism of rosuvastatin combined with benazepril on patients with paroxysmal atrial fibrillation (PAF). METHODS: Seventy patients with PAF were randomized to reagent group and control group. Patients in the reagent group were given amiodarone, rosuvastatin and benazepril, whereas patients in control group were given amiodarone alone. Therapeutic efficacy, serum level of C-reactive protein (CRP) and left atrial diameter (LAD) were observed. RESULTS: After 6 months’ follow-up, PAF times and AF duration were significantly decreased and the total effective rate was elevated in the reagent group compared with those in the control group (P<0.05). Serum level of CRP and the size of the LAD in the reagent group were significantly lower than those in the control group (P<0.05). CONCLUSION: Rosuvastatin combined with benazepril effectively inhibits the occurrence of PAF and the mechanism is probably associated with the effect of inflammatory reaction reduction and myocardium reconstitution inhibition.

参考文献/References

[1]谢百福.胺碘酮联合小剂量氟伐他汀治疗阵发性房颤的临床观察[J].中国实用医药,2007,2(33):131-132.
[2]Shiroshita-Takeshita A,Brundel BJ,Nattel S.Aattel fibrillation：Basic mechanisms，remodeling and triggers[J].J Interv Card Electrophysiol,2005,13(3):181-193.
[3]Aviles RJ, Martin DO,Apperson-Hansen C,et al.Inflammation as a risk factor for atrial fibrillation[J].Circulation,2003,108(24):3006-3010.
[4]Crandall MA,Horne BD,Day JD,et al.Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive Creactive protein incrementally and independently[J].Pacing Clin Electrophysiol,2009,32(5):648-652.
[5]粱海雁,姚传臣,骈 晶,瑞舒伐他汀对心房颤动患者转复后c反应蛋白的影响[J].临床荟萃,2012,27(5):433-434.
[6]Yang Y,Li J,Lin X,et al.Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation[J].J Hum Genet,2009,54(5):277-283.
[7]戚文航.血管紧张素受体拮抗剂与心房颤动[J].中华心血管病杂志,2004,32(11):1042-1043.
[8]Abel T,Fehtr J.Role of rosuvastatin in current lipid-lowering therapy[J].Orv Hetil,2010,151(35):1424-1428.
[9]Kalus JS,Coleman CI,White CM.The impact of suppressing the rennin-angiotensin system on atrial fibrillation[J].J Clin Pharmacol,2006,46(1):21-28.
[10]郑玲英,王彩霞.瑞舒伐他汀联合曲美他嗪治疗高血压伴阵发性心房颤动的疗效观察[J].中国临床保健杂志,2012,15(1):78-80.
[11]Fauehier L,Pierre B,Labriotle A,et al.Antiarrhythmic effect of statin thorapy and atrial fibrillation a meta，analysis of randomized controlledtrials[J].J Am Coll Cardiol,2008,51(8):828-835.
[12]张 茜.老年阵发性心房颤动患者血浆脑钠肽水平的变化及临床意义[J].中国基层医药,2010,17(6):738-739.

备注/Memo

备注/Memo:
收稿日期：2013-10-24.
通讯作者：孙晓斐，主任医师，主要从事冠心病介入治疗、心脏电生理与起搏研究 Email:1178971517@qq.com
作者简介：田飞飞，主治医师，硕士 Email:1178971517@qq.com
更新日期/Last Update: 2014-03-21